The National Cancer Institute has awarded the University of Michigan Rogel Cancer Center a grant worth $33.4 million over five years. At the same time, the center’s designation as a “comprehensive cancer center” was renewed.
As part of the Cancer Moonshot, representatives from government, academic, pharmaceutical and diagnostic companies are launching a new partnership in pursuit of creating an open database for liquid biopsies to potentially accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit.
The University of Michigan Comprehensive Cancer Center is one of 12 sites to joinPrecision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
One of the most common cancer-causing genes has continuously stymied researchers’ efforts to develop treatments against it. Now, researchers have dug deeper and exposed a key interaction that may contribute to why mutations in KRAS lead to cancer.
Researchers found that only 55 percent of colorectal cancer patients who were employed at the time of diagnosis retained their jobs after treatment. Patients who had paid sick leave were nearly twice as likely to retain their jobs as those without paid sick leave.
Researchers at the University of Michigan have identified a potential new approach to fertility preservation for young cancer patients that addresses concerns about beginning cancer treatment immediately and the possibility of reintroducing cancer cells during the fertility preservation process.